PL2379104T3 - Preparaty toksyny botulinowej do wstrzykiwania - Google Patents

Preparaty toksyny botulinowej do wstrzykiwania

Info

Publication number
PL2379104T3
PL2379104T3 PL09837072T PL09837072T PL2379104T3 PL 2379104 T3 PL2379104 T3 PL 2379104T3 PL 09837072 T PL09837072 T PL 09837072T PL 09837072 T PL09837072 T PL 09837072T PL 2379104 T3 PL2379104 T3 PL 2379104T3
Authority
PL
Poland
Prior art keywords
botulinum toxin
toxin formulations
injectable botulinum
injectable
formulations
Prior art date
Application number
PL09837072T
Other languages
English (en)
Polish (pl)
Inventor
Curtis L. Ruegg
Hongran F. Stone
Jacob M. Waugh
Original Assignee
Revance Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42285690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2379104(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Revance Therapeutics, Inc. filed Critical Revance Therapeutics, Inc.
Publication of PL2379104T3 publication Critical patent/PL2379104T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL09837072T 2008-12-31 2009-12-28 Preparaty toksyny botulinowej do wstrzykiwania PL2379104T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14206308P 2008-12-31 2008-12-31
PCT/US2009/069576 WO2010078242A1 (en) 2008-12-31 2009-12-28 Injectable botulinum toxin formulations
EP09837072.9A EP2379104B1 (en) 2008-12-31 2009-12-28 Injectable botulinum toxin formulations

Publications (1)

Publication Number Publication Date
PL2379104T3 true PL2379104T3 (pl) 2018-07-31

Family

ID=42285690

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09837072T PL2379104T3 (pl) 2008-12-31 2009-12-28 Preparaty toksyny botulinowej do wstrzykiwania

Country Status (25)

Country Link
US (5) US9956435B2 (enExample)
EP (2) EP3332805B1 (enExample)
JP (6) JP5866202B2 (enExample)
KR (4) KR102179926B1 (enExample)
CN (2) CN107343859A (enExample)
AU (5) AU2009332947C1 (enExample)
BR (1) BRPI0923731B1 (enExample)
CA (1) CA2749757C (enExample)
CO (1) CO6400199A2 (enExample)
CY (1) CY1120137T1 (enExample)
DK (2) DK2379104T3 (enExample)
ES (2) ES2669020T3 (enExample)
HR (1) HRP20180739T1 (enExample)
HU (1) HUE037595T2 (enExample)
IL (3) IL213668A (enExample)
LT (1) LT2379104T (enExample)
MX (1) MX2011007059A (enExample)
NO (1) NO2379104T3 (enExample)
PL (1) PL2379104T3 (enExample)
PT (1) PT2379104T (enExample)
RU (1) RU2011125775A (enExample)
SG (3) SG172812A1 (enExample)
SI (1) SI2379104T1 (enExample)
SM (1) SMT201800215T1 (enExample)
WO (1) WO2010078242A1 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) * 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
PL2178549T3 (pl) 2007-07-26 2017-03-31 Revance Therapeutics, Inc. Peptyd przeciwdrobnoustrojowy i jego kompozycje
US9345836B2 (en) 2007-10-02 2016-05-24 Medimop Medical Projects Ltd. Disengagement resistant telescoping assembly and unidirectional method of assembly for such
US7967795B1 (en) 2010-01-19 2011-06-28 Lamodel Ltd. Cartridge interface assembly with driving plunger
US10420880B2 (en) 2007-10-02 2019-09-24 West Pharma. Services IL, Ltd. Key for securing components of a drug delivery system during assembly and/or transport and methods of using same
US9656019B2 (en) 2007-10-02 2017-05-23 Medimop Medical Projects Ltd. Apparatuses for securing components of a drug delivery system during transport and methods of using same
EP2195052B1 (en) 2007-10-02 2019-09-04 Medimop Medical Projects Ltd. External drug pump
AU2009223161B2 (en) 2008-03-14 2014-10-30 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
US12097357B2 (en) 2008-09-15 2024-09-24 West Pharma. Services IL, Ltd. Stabilized pen injector
HUE037595T2 (hu) * 2008-12-31 2018-09-28 Revance Therapeutics Inc Injektálható botulinum toxin készítmények
MX366344B (es) * 2009-06-25 2019-07-05 Revance Therapeutics Inc Formulaciones de toxina botulinica libres de albumina.
US10071196B2 (en) 2012-05-15 2018-09-11 West Pharma. Services IL, Ltd. Method for selectively powering a battery-operated drug-delivery device and device therefor
US8157769B2 (en) 2009-09-15 2012-04-17 Medimop Medical Projects Ltd. Cartridge insertion assembly for drug delivery system
US10071198B2 (en) 2012-11-02 2018-09-11 West Pharma. Servicees IL, Ltd. Adhesive structure for medical device
HRP20181869T1 (hr) * 2009-10-21 2019-01-11 Revance Therapeutics, Inc. Metode i sustavi za pročišćavanje nekompleksiranog botulinskog neurotoksina
US10585098B2 (en) 2009-11-23 2020-03-10 The Johns Hopkins University Optimizing diagnostics for galactofuranose containing antigens
WO2011063395A2 (en) * 2009-11-23 2011-05-26 The Johns Hopkins University Lateral flow device for diagnosing microbial infections
US8348898B2 (en) 2010-01-19 2013-01-08 Medimop Medical Projects Ltd. Automatic needle for drug pump
WO2011141907A1 (en) * 2010-05-10 2011-11-17 Medimop Medical Projects Ltd. Low volume accurate injector
KR101134146B1 (ko) * 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
ES2641068T3 (es) * 2011-01-07 2017-11-07 Revance Therapeutics, Inc. Composición tópica que comprende una toxina botulínica y un colorante
USD702834S1 (en) 2011-03-22 2014-04-15 Medimop Medical Projects Ltd. Cartridge for use in injection device
US9072827B2 (en) 2012-03-26 2015-07-07 Medimop Medical Projects Ltd. Fail safe point protector for needle safety flap
CA2889833A1 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US9421323B2 (en) 2013-01-03 2016-08-23 Medimop Medical Projects Ltd. Door and doorstop for portable one use drug delivery apparatus
US9011164B2 (en) 2013-04-30 2015-04-21 Medimop Medical Projects Ltd. Clip contact for easy installation of printed circuit board PCB
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US10107822B2 (en) 2013-12-16 2018-10-23 The Johns Hopkins University Interferon-gamma release assays for diagnosis of invasive fungal infections
EP2952205B1 (en) * 2014-06-06 2017-08-09 Kleiner-Fisman, Galit Botulinum toxin for use in the treatment of paratonia
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
SG11201700736YA (en) * 2014-07-31 2017-02-27 Allergan Inc Formulations of biologics for intravesical instillation
KR20170093780A (ko) * 2014-09-02 2017-08-16 아메리칸 실버, 엘엘씨 보툴리눔 톡신 및 콜로이드 은 입자
RU2694820C9 (ru) * 2014-12-23 2019-08-12 Мерц Фарма Гмбх Унд Ко. Кгаа Контейнер, предварительно заполненный ботулиновым токсином
US10293120B2 (en) 2015-04-10 2019-05-21 West Pharma. Services IL, Ltd. Redundant injection device status indication
CN107427474A (zh) 2015-04-13 2017-12-01 株式会社Lg生活健康 含有调节神经递质释放的成分的可溶性微针
KR102099326B1 (ko) * 2015-04-13 2020-04-09 주식회사 엘지생활건강 폴리페놀 전달용 용해성 마이크로니들
US10149943B2 (en) 2015-05-29 2018-12-11 West Pharma. Services IL, Ltd. Linear rotation stabilizer for a telescoping syringe stopper driverdriving assembly
US11207465B2 (en) 2015-06-04 2021-12-28 West Pharma. Services Il. Ltd. Cartridge insertion for drug delivery device
US9987432B2 (en) 2015-09-22 2018-06-05 West Pharma. Services IL, Ltd. Rotation resistant friction adapter for plunger driver of drug delivery device
US10576207B2 (en) 2015-10-09 2020-03-03 West Pharma. Services IL, Ltd. Angled syringe patch injector
CN108430536B (zh) 2015-10-09 2022-04-08 西医药服务以色列分公司 填充定制注射筒的方法
SG10202004337WA (en) * 2015-10-29 2020-06-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
EP3405227B1 (en) 2016-01-21 2020-06-17 West Pharma. Services Il, Ltd. Force containment in an automatic injector
JP6542481B2 (ja) 2016-01-21 2019-07-10 ウェスト ファーマ サービシーズ イスラエル リミテッド システム
US11311674B2 (en) 2016-01-21 2022-04-26 West Pharma. Services IL, Ltd. Medicament delivery device comprising a visual indicator
US20170209553A1 (en) * 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
US11389597B2 (en) 2016-03-16 2022-07-19 West Pharma. Services IL, Ltd. Staged telescopic screw assembly having different visual indicators
JP6957525B2 (ja) 2016-06-02 2021-11-02 ウェスト ファーマ サービシーズ イスラエル リミテッド ３つの位置による針の退避
US11730892B2 (en) 2016-08-01 2023-08-22 West Pharma. Services IL, Ltd. Partial door closure prevention spring
CN109562229B (zh) 2016-08-01 2021-07-13 西医药服务以色列有限公司 抗旋转药筒销
HUE046449T2 (hu) 2016-09-13 2020-03-30 Allergan Inc Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények
KR102487144B1 (ko) * 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
JP2020507422A (ja) * 2017-02-17 2020-03-12 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 活性成分を含むマイクロニードルアレイ
WO2018175688A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxins for use in therapy
CN107185042B (zh) * 2017-04-29 2020-09-01 杭州维多利亚医疗美容医院有限公司 一种美容注射剂及其制备方法
MX2019013716A (es) * 2017-05-18 2020-10-12 Revance Therapeutics Inc Métodos de tratamiento para la distonía cervical.
JP6921997B2 (ja) 2017-05-30 2021-08-18 ウェスト ファーマ サービシーズ イスラエル リミテッド ウェアラブル注射器のモジュラ駆動トレイン
EP3675900A4 (en) * 2017-08-28 2021-05-05 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
KR20190038292A (ko) * 2017-09-29 2019-04-08 한국프라임제약주식회사 효능 지속시간이 연장된 보툴리눔 독소 조성물
AU2018359962A1 (en) * 2017-11-03 2020-05-28 Revance Therapeutics, Inc. Botulinum toxin formulations and methods of use thereof in plantar fasciitis with extended duration of effect
WO2019113133A1 (en) * 2017-12-04 2019-06-13 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
CN111683703B (zh) 2017-12-22 2022-11-18 西氏医药包装(以色列)有限公司 适用于不同尺寸的药筒的注射器
KR102088104B1 (ko) 2018-06-29 2020-03-11 호서대학교 산학협력단 개망초 꽃 에센셜 오일을 포함하는 신경 근육 관련 질환 예방 및 치료용 조성물
BR122023023068A2 (pt) 2018-12-03 2024-02-20 Eirion Therapeutics, Inc. Uso de agentes grandes, emplastro e kit
CN120919032A (zh) 2019-05-14 2025-11-11 艾里奥治疗公司 延迟峰值效应和/或延长反应持续时间
US12440543B2 (en) 2020-03-31 2025-10-14 Obigen Pharma, Inc. Botulinum toxin type a complex, and formulation thereof and usage method therefor
BR112022020327A2 (pt) * 2020-04-08 2022-12-13 Medytox Inc Formulação de seringa pré-carregada com toxina botulínica
WO2021251789A1 (ko) 2020-06-12 2021-12-16 (주)케어젠 펜타펩타이드를 유효성분으로 포함하는 조성물
KR20220114183A (ko) * 2021-02-08 2022-08-17 주식회사 대웅 장기 저장이 가능한 보툴리눔 독소 동결건조 제형 조성물
WO2023239229A1 (ko) * 2022-06-10 2023-12-14 (주)메디톡스 보툴리눔 독소 안정화 조성물, 이를 포함하는 보툴리눔 독소 제제 및 이에 사용하기 위한 폴리펩티드
KR102714765B1 (ko) * 2023-05-04 2024-10-11 주식회사 파마리서치바이오 Dna 단편 혼합물 및 보툴리눔 독소를 포함하는 보툴리눔 독소의 생체 내 지속성이 증가된 지속성 제제
WO2025064729A1 (en) 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance
WO2025229073A1 (en) * 2024-05-01 2025-11-06 Fastox Pharma Sa Aqueous compositions of dantrolene

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
DE69434443T2 (de) 1993-12-28 2006-05-24 Allergan, Inc., Irvine Verwendung der neutrotoxischen Komponente des Botulinum Toxins zur Muskelschmerzbehandlung
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US20030095927A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
EP1053014A4 (en) 1998-01-26 2004-11-10 Univ Massachusetts BIOLOGICALLY ACTIVE HEMAGGLUTININE TYPE A i (STRIDIUM BOTULINUM) AND METHOD FOR ITS USE
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6358917B1 (en) 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6544548B1 (en) * 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6844324B1 (en) 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
IL149778A0 (en) 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
KR100753765B1 (ko) 2000-02-08 2007-08-31 알레간 인코포레이티드 보툴리눔 독소 약제학적 조성물
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20030215412A1 (en) * 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
EP2364734B1 (en) 2000-07-21 2017-09-06 ReVance Therapeutics, Inc. Multi-component biological transport systems
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US6787517B1 (en) 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
WO2003000193A2 (en) 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
MXPA04007924A (es) 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
AU2003231878A1 (en) 2002-05-31 2003-12-19 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
RU2206337C1 (ru) 2002-10-29 2003-06-20 Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" Лекарственный препарат для лечения мышечных дистоний и способ его получения
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7354740B2 (en) * 2003-09-25 2008-04-08 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
US20060210614A1 (en) 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
PT2985039T (pt) * 2004-03-03 2018-11-09 Revance Therapeutics Inc Aplicação tópica e administração transdérmica de toxinas botulínicas
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
BRPI0513850A (pt) 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
GB2419526A (en) 2004-10-28 2006-05-03 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
EP3210620A1 (en) 2004-08-04 2017-08-30 Ipsen Biopharm Limited Pharmaceutical composition containing botulinum neurotoxin a2
ES2526913T3 (es) 2004-08-04 2015-01-16 Ipsen Biopharm Limited Composición farmacéutica que contiene neurotoxina 2 botulínica
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
CN101160318A (zh) 2005-03-03 2008-04-09 雷文斯治疗公司 用于局部施用和经皮肤递送寡肽的组合物和方法
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
CN101228187A (zh) 2005-03-25 2008-07-23 特拉维夫大学拉莫特有限公司 针对突变p53的共同表位的人合成单链抗体及其用途
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
NZ568216A (en) 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
CN101616682A (zh) 2006-12-29 2009-12-30 雷文斯治疗公司 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法
JP2010528999A (ja) 2007-06-01 2010-08-26 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー ボツリヌストキシンの神経毒成分に基づいた、温度安定な筋弛緩薬を固体形態で供給する方法
PL2178549T3 (pl) * 2007-07-26 2017-03-31 Revance Therapeutics, Inc. Peptyd przeciwdrobnoustrojowy i jego kompozycje
WO2009056651A1 (en) 2007-11-02 2009-05-07 Cytos Biotechnology Ag Angiotensin-carrier formulation
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
KR20090120222A (ko) 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
US20100196445A1 (en) * 2008-11-12 2010-08-05 David Nathaniel E Systems and methods for delivery of biologically active agents
KR20110106346A (ko) 2008-12-10 2011-09-28 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
HUE037595T2 (hu) * 2008-12-31 2018-09-28 Revance Therapeutics Inc Injektálható botulinum toxin készítmények
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
MX366344B (es) 2009-06-25 2019-07-05 Revance Therapeutics Inc Formulaciones de toxina botulinica libres de albumina.
HRP20181869T1 (hr) 2009-10-21 2019-01-11 Revance Therapeutics, Inc. Metode i sustavi za pročišćavanje nekompleksiranog botulinskog neurotoksina
AU2010313529A1 (en) 2009-10-30 2012-04-12 Duoject Medical Systems, Inc. Device and method for topical application of therapeutics or cosmetic compositions
WO2012048854A2 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
ES2641068T3 (es) 2011-01-07 2017-11-07 Revance Therapeutics, Inc. Composición tópica que comprende una toxina botulínica y un colorante
ES2636680T5 (es) 2011-03-31 2023-10-31 Medy Tox Inc Preparación liofilizada de toxina botulínica
US20130224268A1 (en) 2012-02-27 2013-08-29 Newgen Biopharma Corp. Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
RU2694820C9 (ru) 2014-12-23 2019-08-12 Мерц Фарма Гмбх Унд Ко. Кгаа Контейнер, предварительно заполненный ботулиновым токсином
TWI777955B (zh) 2016-05-27 2022-09-21 英商益普生生物製藥有限公司 神經毒素調配物

Also Published As

Publication number Publication date
AU2016238949A1 (en) 2016-10-27
AU2023229550A1 (en) 2023-11-23
BRPI0923731A2 (pt) 2016-01-19
US20100168023A1 (en) 2010-07-01
LT2379104T (lt) 2018-04-10
CO6400199A2 (es) 2012-03-15
JP2012514003A (ja) 2012-06-21
AU2016238949C1 (en) 2018-11-01
US11471708B2 (en) 2022-10-18
JP2015134784A (ja) 2015-07-27
EP3332805B1 (en) 2022-02-23
KR20110117667A (ko) 2011-10-27
CN102300584A (zh) 2011-12-28
KR20200131348A (ko) 2020-11-23
MX2011007059A (es) 2011-09-15
IL254558B (en) 2021-04-29
US20200215357A1 (en) 2020-07-09
JP2019194251A (ja) 2019-11-07
AU2018253620B2 (en) 2020-10-29
IL213668A (en) 2017-11-30
SMT201800215T1 (it) 2018-05-02
ES2669020T3 (es) 2018-05-23
SG10201405582YA (en) 2014-10-30
EP2379104A1 (en) 2011-10-26
EP3332805A1 (en) 2018-06-13
JP6976997B2 (ja) 2021-12-08
AU2021200561B2 (en) 2023-06-15
AU2009332947A1 (en) 2011-07-07
SI2379104T1 (en) 2018-05-31
CY1120137T1 (el) 2018-12-12
DK3332805T3 (da) 2022-05-16
JP6559849B2 (ja) 2019-08-14
BRPI0923731B1 (pt) 2024-02-06
EP2379104B1 (en) 2018-02-28
AU2018253620A1 (en) 2018-11-22
EP2379104A4 (en) 2013-11-27
IL254558A0 (en) 2017-11-30
SG172812A1 (en) 2011-08-29
KR102005930B1 (ko) 2019-07-31
CN107343859A (zh) 2017-11-14
US20180214717A1 (en) 2018-08-02
JP6145465B2 (ja) 2017-06-14
AU2009332947B2 (en) 2016-07-07
KR102179926B1 (ko) 2020-11-17
AU2023229550B2 (en) 2025-09-11
SG10202100698QA (en) 2021-02-25
HK1256878A1 (en) 2019-10-04
AU2021200561A1 (en) 2021-02-25
KR20170077292A (ko) 2017-07-05
ES2908616T3 (es) 2022-05-03
AU2009332947C1 (en) 2019-01-03
US20110268765A1 (en) 2011-11-03
CA2749757A1 (en) 2010-07-08
JP2022028770A (ja) 2022-02-16
CA2749757C (en) 2024-03-26
JP2017178954A (ja) 2017-10-05
KR20190091376A (ko) 2019-08-05
US9956435B2 (en) 2018-05-01
JP5866202B2 (ja) 2016-02-17
AU2016238949B2 (en) 2018-07-26
KR101753242B1 (ko) 2017-07-20
US20240058628A1 (en) 2024-02-22
DK2379104T3 (en) 2018-04-30
KR102363878B1 (ko) 2022-02-16
PT2379104T (pt) 2018-03-26
HUE037595T2 (hu) 2018-09-28
JP2018184460A (ja) 2018-11-22
HRP20180739T1 (hr) 2018-06-29
NO2379104T3 (enExample) 2018-07-28
IL213668A0 (en) 2011-07-31
IL281675A (en) 2021-05-31
WO2010078242A1 (en) 2010-07-08
RU2011125775A (ru) 2013-02-10

Similar Documents

Publication Publication Date Title
SG10201405582YA (en) Injectable Botulinum Toxin Formulations
IL268980A (en) Botulinum toxin formulations without albumin
GB2462811B (en) Improved autoinjector
GB0800927D0 (en) Botulinum neurotoxin vaccine
GB0810554D0 (en) Herbicde composition
DK2301489T3 (en) Tredimensionelt ortopædisk udstyr til rygsøjlen
GB0801119D0 (en) Composition
PL2334177T3 (pl) Preparat toksyny peptydowej
GB0809808D0 (en) Composition
GB0806814D0 (en) Improved autoinjector
GB0811743D0 (en) Composition
GB0801401D0 (en) Composition
GB0810359D0 (en) Composition
GB0812740D0 (en) Composition
GB0806948D0 (en) Composition
GB0819356D0 (en) Tie
GB0813589D0 (en) Composition
GB0809983D0 (en) Composition
GB0804031D0 (en) Composition
GB0813165D0 (en) Composition
GB0814149D0 (en) Polyol compositions
AU2008902603A0 (en) Injectable Formulations
GB0814880D0 (en) Tie
GB0801497D0 (en) Composition
GB0808624D0 (en) Composition